Adelaide Research & Scholarship: Search

Search

Results 1-10 of 16 (Search time: 0.002 seconds).

previous
1
2
next

Item hits:

Preview	Issue Date	Title	Author(s)
	2014	Weight gain on androgen deprivation therapy: which patients are at highest risk?	Seible, D.; Gu, X.; Hyatt, A.; Beard, C.; Choueiri, T.; Efstathiou, J.; Miyamoto, D.; Mitin, T.; Martin, N.; Sweeney, C.; Trinh, Q.; Beckman, J.; Basaria, S.; Nguyen, P.
	2014	Phase 2 trial of dovitinib in patients with progressive FGFR3-mutated or FGFR3 wild-type advanced urothelial carcinoma	Milowsky, M.; Dittrich, C.; Durán, I.; Jagdev, S.; Millard, F.; Sweeney, C.; Bajorin, D.; Cerbone, L.; Quinn, D.; Stadler, W.; Rosenberg, J.; Lochheed, M.; Sen, P.; Squires, M.; Shi, M.; Sternberg, C.
	2014	Cabozantinib in chemotherapy-pretreated metastatic castration-resistant prostate cancer: results of a phase II nonrandomized expansion study	Smith, M.; Sweeney, C.; Corn, P.; Rathkopf, D.; Smith, D.; Hussain, M.; George, D.; Higano, C.; Harzstark, A.; Sartor, A.; Vogelzang, N.; Gordon, M.; De Bono, J.; Haas, N.; Logothetis, C.; Elfiky, A.; Scheffold, C.; Laird, A.; Schimmoller, F.; Basch, E.; et al.
	2014	'Charting a new course for prostate cancer' - currying favor for docetaxel in hormone-sensitive metastatic prostate cancer	Voskoboynik, M.; Staffurth, J.; Malik, Z.; Sweeney, C.; Chowdhury, S.
	2014	Racial disparities in prostate cancer - specific mortality in men with low-risk prostate cancer	Mahal, B.; Aizer, A.; Ziehr, D.; Hyatt, A.; Choueiri, T.; Hu, J.; Hoffman, K.; Sweeney, C.; Beard, C.; D'Amico, A.; Martin, N.; Kim, S.; Trinh, Q.; Nguyen, P.
	2014	Enhancer RNAs participate in androgen receptor-driven looping that selectively enhances gene activation	Hsieh, C.; Fei, T.; Chen, Y.; Li, T.; Gao, Y.; Wang, X.; Sun, T.; Sweeney, C.; Lee, G.; Chen, S.; Balk, S.; Liu, X.; Brown, M.; Kantoff, P.
	2014	MiR-221 promotes the development of androgen independence in prostate cancer cells via downregulation of HECTD2 and RAB1A	Sun, T.; Wang, X.; He, H.; Sweeney, C.; Liu, S.; Brown, M.; Balk, S.; Lee, G.; Kantoff, P.
	2014	Neoadjuvant dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin with pegfilgrastim support in muscle-invasive urothelial cancer: pathologic, radiologic, and biomarker correlates	Choueiri, T.; Jacobus, S.; Bellmunt, J.; Qu, A.; Appleman, L.; Tretter, C.; Bubley, G.; Stack, E.; Signoretti, S.; Walsh, M.; Steele, G.; Hirsch, M.; Sweeney, C.; Taplin, M.; Kibel, A.; Krajewski, K.; Kantoff, P.; Ross, R.; Rosenberg, J.
	2014	Racial disparities in an aging population: the relationship between age and race in the management of African American men with high-risk prostate cancer	Mahal, B.; Ziehr, D.; Aizer, A.; Hyatt, A.; Lago-Hernandez, C.; Choueiri, T.; Elfiky, A.; Hu, J.; Sweeney, C.; Beard, C.; D'Amico, A.; Martin, N.; Kim, S.; Lathan, C.; Trinh, Q.; Nguyen, P.
	2014	Failure to suppress markers of bone turnover on first-line hormone therapy for metastatic prostate cancer is associated with shorter time to skeletal-related event	Hahn, N.; Yiannoutsos, C.; Kirkpatrick, K.; Sharma, J.; Sweeney, C.